title: Soluble interleukin-2 receptor level on day 7 as a predictor of graft-versus-host disease after HLA-haploidentical stem cell transplantation using reduced-intensity conditioning.
abstract: In the present study, we analyzed the kinetics of serum soluble interleukin-2 receptor (sIL-2R) using data from 77 patients undergoing HLA-haploidentical transplantation using reduced-intensity conditioning (RIC), who were at an advanced stage or at high risk for relapse, to clarify the usefulness of sIL-2R as a biomarker of acute graft-versus-host disease (GVHD). Anti-T-lymphocyte globulin and methylprednisolone were used as GVHD prophylaxis. While the median sIL-2R in 38 patients not developing GVHD was suppressed at levels <740 U/ml, sIL-2R in 25 patients developing severe GVHD peaked on day 11 (1,663 U/ml), and thereafter decreased to <1,000 U/ml after day 30. The occurrence of GVHD was not limited to times of high sIL-2R level, but occurred at any time point on the sIL-2R curve. Most patients developing GVHD, however, experienced a higher sIL-2R level early in their transplant course. The combination of RIC and glucocorticoids sufficiently suppressed sIL-2R levels after HLA-haploidentical transplantation. In a multivariate analysis to identify factors associated with GVHD, day 7 sIL-2R >810 U/ml was the only factor significantly associated with the occurrence of severe GVHD (p = 0.0101).
authors.affiliation: Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan.
authors.forename: Katsuji
authors.initials: K
authors.lastname: Kaida
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Ikegame
authors.forename: Junko
authors.initials: J
authors.lastname: Ikemoto
authors.forename: Rie
authors.initials: R
authors.lastname: Murata
authors.forename: Reiko
authors.initials: R
authors.lastname: Irie
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yoshihara
authors.forename: Shinichi
authors.initials: S
authors.lastname: Ishii
authors.forename: Masaya
authors.initials: M
authors.lastname: Okada
authors.forename: Takayuki
authors.initials: T
authors.lastname: Inoue
authors.forename: Hiroya
authors.initials: H
authors.lastname: Tamaki
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Soma
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Fujimori
authors.forename: Shunro
authors.initials: S
authors.lastname: Kai
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Ogawa
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006086:Graft vs Host Disease / Q000097:blood* / Q000175:diagnosis / Q000209:etiology*; D006680:HLA Antigens / Q000235:genetics* / Q000276:immunology*; D006239:Haplotypes; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012372:ROC Curve; D015375:Receptors, Interleukin-2 / Q000097:blood*; D012189:Retrospective Studies; D013997:Time Factors; D019172:Transplantation Conditioning / Q000009:adverse effects; D055815:Young Adult
chemical_list: D006680:HLA Antigens; D015375:Receptors, Interleukin-2